Multidomain intervention and/or omega‐3 in nondemented elderly subjects according to amyloid status.

Introduction: The Multidomain Alzheimer Preventive Trial (MAPT) assessed the efficacy of omega‐3 fatty acid supplementation, a multidomain intervention (MI), or a combination of both on cognition. Impact according to cerebral amyloid status was evaluated by PET scan. Methods: Participants were nondemented and had memory complaints, limitation in one instrumental activity of daily living, or slow gait. The primary outcome was a change from baseline in 36 months measured with a cognitive composite Z score. Results: No effect was observed on cognition in the negative amyloid group (n = 167). In the positive amyloid group (n = 102), we observed a difference of 0.708 and 0.471 in the cognitive composite score between the MI plus omega‐3 fatty acid group, the MI alone group, and the placebo group, respectively. Discussion: MI alone or in combination with omega‐3 fatty acids was associated with improved primary cognitive outcome in subjects with positive amyloid status. Trial Registration: ClinicalTrials.gov Identifier: NCT01513252. [ABSTRACT FROM AUTHOR]